David A Johnson

Summary

Publications

  1. ncbi A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease
    D A Johnson
    Department of Medicine, Gastroenterology Division, Eastern Virginia Medical School, Norfolk, VA, USA
    Aliment Pharmacol Ther 22:129-34. 2005
  2. ncbi Treating chronic constipation : How should we interpret the recommendations?
    David A Johnson
    Department of Gastroenterology, Eastern VA Medical School, Norfolk, Virginia 23502, USA
    Clin Drug Investig 26:547-57. 2006
  3. ncbi Medical therapy of reflux laryngitis
    David A Johnson
    Department of Internal Medicine, Eastern VA Medical School, Norfolk VA, USA
    J Clin Gastroenterol 42:589-93. 2008
  4. ncbi Evaluation of esophageal function/pH in endoscopic therapy for gastroesophageal reflux disease
    David A Johnson
    Department of Gastroenterology, Eastern Virginia School of Medicine, 700 W Olney Road, Norfolk, VA 23501, USA
    Gastrointest Endosc Clin N Am 15:333-45. 2005
  5. ncbi CT and radiation-related cancer risk-time for a paradigm shift?
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, Suite 114, 885 Kempsville Road, Norfolk, VA 23502, USA
    Nat Rev Gastroenterol Hepatol 6:738-40. 2009
  6. ncbi Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease
    David A Johnson
    Eastern Virginia Medical School, Division of Gastroenterology, Norfolk, 23505, USA
    Gastroenterology 126:660-4. 2004
  7. ncbi Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, 885 Kempsville Road, Suite 114, Norfolk, VA, 23505, USA
    Curr Gastroenterol Rep 12:167-74. 2010
  8. ncbi Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages
    David A Johnson
    Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia 23505, USA
    Pharmacotherapy 23:731-4. 2003
  9. ncbi Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances
    D Johnson
    Gastroenterology Division, Eastern Virginia Medical School, Norfolk, VA 23502, USA
    Aliment Pharmacol Ther 32:182-90. 2010
  10. ncbi Review of esomeprazole in the treatment of acid disorders
    David A Johnson
    Eastern Virginia Medical School, Division of Gastroenterology, 885 Kempsville Road, Suite 114, Norfolk, VA 23505, USA
    Expert Opin Pharmacother 4:253-64. 2003

Collaborators

Detail Information

Publications40

  1. ncbi A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease
    D A Johnson
    Department of Medicine, Gastroenterology Division, Eastern Virginia Medical School, Norfolk, VA, USA
    Aliment Pharmacol Ther 22:129-34. 2005
    ..Intragastric acid suppression is the most direct measure of the pharmacodynamic efficacy of proton pump inhibitors, which are the most effective drugs for acid-related diseases...
  2. ncbi Treating chronic constipation : How should we interpret the recommendations?
    David A Johnson
    Department of Gastroenterology, Eastern VA Medical School, Norfolk, Virginia 23502, USA
    Clin Drug Investig 26:547-57. 2006
    ..It is hoped that these advancements will help clinicians select effective medical regimens for patients with chronic constipation...
  3. ncbi Medical therapy of reflux laryngitis
    David A Johnson
    Department of Internal Medicine, Eastern VA Medical School, Norfolk VA, USA
    J Clin Gastroenterol 42:589-93. 2008
    ..This review highlights the current challenges for establishing the diagnosis of GERD-related LPR and focuses on the limitations of medical therapy directed toward gastric acid suppression...
  4. ncbi Evaluation of esophageal function/pH in endoscopic therapy for gastroesophageal reflux disease
    David A Johnson
    Department of Gastroenterology, Eastern Virginia School of Medicine, 700 W Olney Road, Norfolk, VA 23501, USA
    Gastrointest Endosc Clin N Am 15:333-45. 2005
    ..For patients being evaluated for endoscopic GERD therapy, the author recommends comprehensive esophageal testing and pH testing...
  5. ncbi CT and radiation-related cancer risk-time for a paradigm shift?
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, Suite 114, 885 Kempsville Road, Norfolk, VA 23502, USA
    Nat Rev Gastroenterol Hepatol 6:738-40. 2009
    ..Appropriate discussion between physicians and patients of the risks associated with radiographic studies is warranted to inform patients of the longitudinal risks of subsequent testing...
  6. ncbi Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease
    David A Johnson
    Eastern Virginia Medical School, Division of Gastroenterology, Norfolk, 23505, USA
    Gastroenterology 126:660-4. 2004
    ..We therefore assessed the relationship between age, severe heartburn symptoms, and severe erosive esophagitis...
  7. ncbi Safety of proton pump inhibitors: current evidence for osteoporosis and interaction with antiplatelet agents
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, 885 Kempsville Road, Suite 114, Norfolk, VA, 23505, USA
    Curr Gastroenterol Rep 12:167-74. 2010
    ..This report reviews the scientific hypothesis, biologic plausibility, and the most recent clinical trial data for both areas of controversy...
  8. ncbi Stability of esomeprazole capsule contents after in vitro suspension in common soft foods and beverages
    David A Johnson
    Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia 23505, USA
    Pharmacotherapy 23:731-4. 2003
    ..To determine the in vitro stability of esomeprazole pellets from an opened capsule after suspension in various common soft foods and beverages...
  9. ncbi Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances
    D Johnson
    Gastroenterology Division, Eastern Virginia Medical School, Norfolk, VA 23502, USA
    Aliment Pharmacol Ther 32:182-90. 2010
    ..Nighttime heartburn, common among patients with gastro-oesophageal reflux disease (GERD), is associated with substantial clinical effects. GERD-related sleep disturbances are underappreciated and undertreated...
  10. ncbi Review of esomeprazole in the treatment of acid disorders
    David A Johnson
    Eastern Virginia Medical School, Division of Gastroenterology, 885 Kempsville Road, Suite 114, Norfolk, VA 23505, USA
    Expert Opin Pharmacother 4:253-64. 2003
    ..Esomeprazole is well-tolerated, with a spectrum and incidence of adverse events similar to those associated with omeprazole...
  11. ncbi Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors
    David A Johnson
    Eastern Virginia Medical School, Gastroenterology, 885 Kempsville Rd, Norfolk, VA 23502, USA
    Expert Opin Pharmacother 11:1541-8. 2010
    ..There is a clear need for GERD therapies beyond the PPIs...
  12. ncbi Prevention of relapse of healed reflux esophagitis is related to the duration of intragastric pH > 4
    David A Johnson
    Eastern Virginia Medical School, Norfolk, VA 23502, USA
    J Clin Gastroenterol 44:475-8. 2010
    ..001). These findings indicate that long-term maintenance of healed RE is related to the extent of acid suppression in a 24-hour period...
  13. ncbi Enteryx for gastroesophageal reflux disease
    David A Johnson
    Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, VA 23501, USA
    Expert Rev Med Devices 2:19-26. 2005
    ..Multicenter clinical trials have demonstrated that the Enteryx procedure safely and effectively eliminates, or significantly reduces, proton-pump inhibitor use in approximately 84% of patients at 1 year, and 72% of patients at 2 years...
  14. ncbi Enteryx implantation for GERD: expanded multicenter trial results and interim postapproval follow-up to 24 months
    Lawrence B Cohen
    Division of Gastroenterology, Mount Sinai Hospital, New York, New York, USA
    Gastrointest Endosc 61:650-8. 2005
    ..CONCLUSIONS: This investigation provides evidence for sustained effectiveness and safety of implantation of Enteryx in the esophagus in PPI-dependent patients with GERD...
  15. ncbi Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial
    David A Johnson
    Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia, USA
    Am J Gastroenterol 98:1921-30. 2003
    ..The effects of implantation are long-lasting, and morbidity is transient and minimal. The procedure requires basic endoscopic skills and seems to provide a useful option in the effective clinical management of GERD...
  16. ncbi Endoscopic therapy for GERD--baking, sewing, or stuffing: an evidence-based perspective
    David A Johnson
    Section of Gastroenterology, Eastern Virginia Medical School, Norfolk, Virgina, USA
    Rev Gastroenterol Disord 3:142-9. 2003
    ..Additionally, the risk/benefit profile must be carefully evaluated for each of these interventions before considering it a viable treatment strategy...
  17. ncbi Heartburn severity does not predict disease severity in patients with erosive esophagitis
    M Brian Fennerty
    Division of Gastroenterology, Oregon Health and Science University, Portland, Oregon, USA
    MedGenMed 8:6. 2006
    ..For patients with gastroesophageal reflux disease (GERD), it is often assumed by treating physicians that the severity of heartburn correlates with the severity of erosive esophagitis (EE)...
  18. ncbi Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Rev Cardiovasc Med 6:S15-22. 2005
    ..It is important for the cardiologist to fully understand the UGI risk profiles so that each patient is evaluated as a candidate for possible preventive co-therapy with appropriate anti-ulcer medication...
  19. ncbi Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Rev Gastroenterol Disord 8:98-108. 2008
    ..These newer PPI formulations offer significant hope for the advancement of treatment opportunities...
  20. ncbi Alternative dosing for PPI therapy: rationale and options
    David A Johnson
    Section of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia, USA
    Rev Gastroenterol Disord 3:S10-5. 2003
    ..Therefore, a clear understanding of alternative dosing formulations and related efficacies is key in order for the clinician to select the most appropriate agent and strategy to optimize outcomes and cost-effectiveness for each patient...
  21. ncbi Gastroesophageal reflux disease in the elderly--a prevalent and severe disease
    David A Johnson
    Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia, USA
    Rev Gastroenterol Disord 4:S16-24. 2004
    ..Physicians treating elderly patients with GERD need to recognize that these patients require more potent and sustained acid inhibition to effectively and consistently achieve optimal clinical outcomes...
  22. ncbi Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial
    David A Johnson
    Eastern VA School of Medicine, Norfolk, Virginia, USA
    Am J Gastroenterol 100:1914-22. 2005
    ..6 h; esomeprazole 20 mg, 12.3 h; placebo, 6.2 h). CONCLUSIONS: Esomeprazole reduced nighttime heartburn and GERD-related sleep disturbances and improved sleep quality and work productivity...
  23. ncbi Gastroesophageal reflux disease and sleep disorders: a wake-up call for physicians and their patients
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Rev Gastroenterol Disord 5:S3-11. 2005
    ..Clinicians are advised to take a proactive stance in evaluating patients with GERD for unrecognized sleep disorders and ascertaining whether patients with sleep disorders have GERD symptoms as well...
  24. ncbi Endoscopic therapy for gastroesophageal reflux disease: a systematic review
    D A Johnson
    Eastern VA School of Medicine, Norfolk, VA 23505, USA
    Minerva Gastroenterol Dietol 50:239-51. 2004
    ..The risk/benefit profile, long term durability and cost effectiveness should be considered in all patients being considered when evaluating each of the endoscopic therapies for GERD...
  25. ncbi Persistent vertical binocular diplopia after cataract surgery
    D A Johnson
    Grene Vision Group, 655 North Woodlawn, Wichita, KS 67208, USA
    Am J Ophthalmol 132:831-5. 2001
    ..To report the incidence of, and factors associated with, persistent vertical diplopia after cataract surgery...
  26. ncbi Peripheral steroid sulfatase inhibition potentiates improvement of memory retention for hippocampally administered dehydroepiandrosterone sulfate but not pregnenolone sulfate
    J F Flood
    Geriatric Research Education and Clinical Center GRECC, VA Medical Center, St Louis, MO 63106, USA
    Psychoneuroendocrinology 24:799-811. 1999
    ..It was concluded that EMATE, acting peripherally, increased plasma levels of DHEAS which entered the brain and added to the effect of centrally administered DHEAS. The failure of EMATE to potentiate PREGS is discussed...
  27. ncbi Feasibility and safety of string, wireless capsule endoscopy in the diagnosis of Barrett's esophagus
    Francisco C Ramirez
    Gastroenterology Section, Department of Medicine, Carl T. Hayden Veterans Affairs Medical Center, Phoenix, AZ 85012, USA
    Gastrointest Endosc 61:741-6. 2005
    ..CONCLUSIONS: String-capsule endoscopy was feasible, safe, and highly acceptable, and was preferred by patients and may prove to be more cost effective than screening EGD...
  28. ncbi Endoscopic, deep mural implantation of Enteryx for the treatment of GERD: 6-month follow-up of a multicenter trial
    David A Johnson
    Division of Gastroenterology, Eastern Virginia School of Medicine, Norfolk 23502, USA
    Am J Gastroenterol 98:250-8. 2003
    ....
  29. ncbi Endpoints for the assessment of response to gastroesophageal reflux disease therapy--what are the appropriate measures of "success"?
    David A Johnson
    Division of Gastroenterology, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Rev Gastroenterol Disord 4:118-28. 2004
    ..This review focuses on the questions that should be raised by clinicians in their evidence-based evaluation of the outcomes achieved in these GERD intervention trials...
  30. ncbi Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study
    N Chand
    Division of Gastroenterology and Sleep Physiology Laboratory, Eastern Virginia Medical School, Norfolk, VA, USA
    Aliment Pharmacol Ther 20:969-74. 2004
    ..Actigraphy may be inappropriate for measurement of sleep disturbance in gastro-oesophageal reflux disease patients...
  31. ncbi Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety
    D A Johnson
    Eastern Virginia School of Medicine, Norfolk, USA
    Am J Gastroenterol 96:27-34. 2001
    ..CONCLUSIONS: Esomeprazole is effective and well tolerated in the maintenance of a healing erosive esophagitis. Esomeprazole 40 mg and 20 mg maintain healing in over 90% of patients while providing effective control of heartburn symptoms...
  32. ncbi Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date
    Raj Majithia
    Division of Gastroenterology, Washington Hospital Center, Washington, DC, USA
    Drugs 72:171-9. 2012
    ..This evidence-based review will address the management and safety of PPI therapy during pregnancy and lactation, and briefly review the pathogenesis, clinical presentation and diagnosis of GERD in this population...
  33. ncbi Symptoms of gastro-oesophageal reflux disease and the severity of obstructive sleep apnoea syndrome are not related in sleep disorders center patients
    H-N Kim
    Department of Internal Medicine, University of Virginia, Charlottesville, VA, USA
    Aliment Pharmacol Ther 21:1127-33. 2005
    ..CONCLUSION: In a large group of patients referred to a sleep disorders center, there was no relationship between OSAS and GERD symptoms. Also, there was no relationship between the severity of OSAS and the likelihood of GERD symptoms...
  34. ncbi Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis
    Donald O Castell
    Department of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston 29425, USA
    Am J Gastroenterol 97:575-83. 2002
    ..CONCLUSIONS: Esomeprazole (40 mg) is more effective than lansoprazole (30 mg) in healing erosive esophagitis and resolving heartburn. Healing rates are consistently high with esomeprazole, irrespective of baseline disease severity...
  35. ncbi Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams
    Kenneth R DeVault
    Mayo Clinic College of Medicine, Jacksonville, Florida, USA
    Clin Gastroenterol Hepatol 4:852-9. 2006
    ..Both treatments were well-tolerated. CONCLUSION: Esomeprazole 20 mg is more effective than lansoprazole 15 mg in maintaining endoscopic/symptomatic remission in patients with healed erosive esophagitis...
  36. ncbi A randomized pilot study of near activities versus non-near activities during patching therapy for amblyopia
    Jonathan M Holmes
    Jaeb Center for Health Research, 15310 Amberly Drive, Tampa, FL 33647, USA
    J AAPOS 9:129-36. 2005
    ..A secondary aim was to obtain a preliminary estimate of the effect of near versus non-near activities on amblyopic eye visual acuity, when combined with 2 hours of daily patching...
  37. ncbi Orthopedic surgery options for the treatment of primary osteosarcoma
    German A Marulanda
    Sarcoma Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:13-20. 2008
    ..This review discusses the advantages and disadvantages of the various types of amputations and the limb-salvaging techniques for the treatment of osteosarcoma...
  38. ncbi Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529
    Jay T Evans
    Corixa Corporation, Hamilton, MT 59840, USA
    Expert Rev Vaccines 2:219-29. 2003
    ..One of these compounds, Ribi.529 (RC-529), has emerged as a leading adjuvant with a similar efficacy and safety profile to MPL adjuvant in both preclinical and clinical studies...
  39. ncbi Critical GI issues for the cardiologist: new insights and understanding. Introduction
    David P Faxon
    Section of Cardiology, University of Chicago, Chicago, Illinois, USA
    Rev Cardiovasc Med 6:S1-2. 2005
  40. ncbi Papain: a novel urine adulterant
    David L Burrows
    Section of Toxicology, Department of Pharmacology, James H Quillen College of Medicine, East Tennessee State University, Johnson City, 37614, USA
    J Anal Toxicol 29:275-95. 2005
    ..No adulterated specimens were rendered invalid based on the SAMHSA guidelines. Immediate FPIA analysis is suggested to minimize the interfering effects of papain with regards to primary drug screening...